Analysis on the use of medicines in treatment of benign prostatic hyperplasia in sample hospitals under the national volume-based procurement policy
Objective To explore the impact of national volume-based procurement policies on the use of medicines in treatment of benign prostatic hyperplasia(BPH)and provide data support for the rational clinical use of medicines in BPH treatment.Methods Data on the use of BPH treatment medications from 2019 to 2023 were extracted from the Chinese Medicine Economic Information Network(CMEI),covering 892 hospitals(including 645 tertiary hospitals and 247 secondary hospitals).The changes in various indicators,including the consumption sum,Defined daily doses(DDDs),Defined daily dose cost(DDDc),and the ranking ratio(B/A)of these drugs were analyzed and compared.Results From 2019 to 2023,due to the influence of relevant policies,the overall consumption sums of medicines used in the sample hospitals in BPH treatment showed a trend of decreasing first and then rising steadily.The DDDs showed an overall upward trend,while the DDDc demonstrated a gradual decline.Tamsulosin and finasteride consistently ranked first and second in DDDs.The B/A value for tamsulosin was significantly higher than that of other BPH treatment medications.Conclusion The implementation of national centralized drug volume-based procurement policies and other policies from 2019 to 2023 had effectively reduced the economic burden of patients with benign prostatic hyperplasia.Tamsulosin and finasteride,which had the highest B/A in the two categories of α-blockers and 5α-reductase inhibitors,dominated the market for BPH treatment.The clinical use of BPH treatment medications was relatively rational.
national centralized drug volume-based procurementdrugs for the treatment of benign prostatic hyperplasiadefined daily dosesdefined daily dose cost
万方数据
维普
